CVD Prevention Models in Sub-Saharan Africa: Insights and Gaps

By João L. Carapinha

February 24, 2025

How can decision analytic models improve cardiovascular disease prevention in Sub-Saharan Africa? A recent article on the application of decision analytic modelling to cardiovascular disease prevention in Sub-Saharan Africa explored the use of decision analytic models (DAMs) for evaluating interventions aimed at cardiovascular disease (CVD) prevention in Sub-Saharan Africa (SSA). It highlights that CVDs represent a significant burden in SSA, with an upward trend observed over the last three decades.

The review encompasses 27 studies from eight SSA countries, concentrating on model-based economic evaluations of CVD prevention models. Most studies focused on primary CVD prevention, with pharmacological interventions, particularly antihypertensives and statins, being most common. Markov models were frequently utilized, and the Framingham risk equations were applied to estimate 10-year CVD risk.

Notes from the Study

Most studies centered on primary CVD prevention, with pharmacological interventions being the predominant focus. Markov models and microsimulation models were the most utilized, with Markov models appearing in 13 studies and microsimulation models in seven. Only seven studies integrated equity dimensions, primarily through subgroup analysis, focusing on gender, socioeconomic, and regional inequalities.

Significant data gaps emerged, especially concerning intervention effectiveness and CVD risk equations, highlighting a lack of local data for generating 10-year CVD risk assessments. The mean quality score of the papers was 68.9%, although inconsistencies and data limitations were apparent, with only three studies undertaking model validation.

Health Economic Implications

The findings emphasize the necessity for enhanced health economic evaluations that factor in equity dimensions to guide policy decisions on CVD prevention in SSA. Longitudinal studies are essential for refining CVD risk prediction and local health outcome valuation studies. The review indicated that policymakers must prioritize cost-effective and equitable interventions to strive for universal health coverage (UHC). Strengthening primary healthcare systems is vital for scaling up effective CVD prevention models.

Future Studies

Future studies should aim to address primordial prevention and lifestyle interventions, which are currently undervalued. There is also an urgent need for improved model validation, calibration, and stakeholder engagement in the modeling process.

The review highlighted the importance of adhering to best practices in developing DAMs, such as utilizing local data, ensuring model validation, and maintaining transparency in the modeling process. The absence of local data for generating 10-year CVD risk equations and utility values for QALYs reveals significant research gaps. Incorporating equity considerations in economic evaluations is crucial, particularly through newer methods like extended and distributional cost-effectiveness analyses. There is a call for increased emphasis on longitudinal studies and local health valuation studies to enhance the accuracy and relevance of CVD prevention models in SSA.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.